A Randomized, Double-Blind, Placebo-Controlled, Multi-center, Parallel Group Study to Determine the Efficacy and Safety of Residronate (NE-58095)in the Treatment of Post Menopausal Women with Established Osteoporosis-Related Vertebral Deformities

Publications

Journal Articles:

• Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner TN, Keller M, Chesnut III CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999): Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis-a randomized controlled trial. JAMA 282:1344-1352.

Abstracts:

• Watts N., Hangartner T., Chesnut C., Genant H., Miller P., Eriksen E., Chimes A., Axelrod D., McKeever C (1999): Risedronate treatment prevents vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 64 (Suppl. 1): S42.

• Watts N, Roux C, Genant H, Adami S, Hangartner T, Miller P, Sorensen O, Hooper M, Ethgen D, Valent D (1999): Risedronate reduces vertebral fracture risk after the first year of treatment in post menopausal women with established osteoporosis. J Bone and Mineral Res14: S136.

People

Hangartner TN                        thangart@cs.wright.edu